AHA 2021 Bentracimab has been developed as a specific reversal agent for the P2Y12 inhibitor ticagrelor. Prof. Bhatt gives a summary of an interim analysis of the REVERSE-IT study with bentracimab.

AHA 2021 Milvexian is a new oral FXIa inhibitor and has been examined for thromboprophylaxis in patients after knee replacement. Prof. Weitz shares the results of a phase 2 study.

AHA 2021 An interim analysis of the REVERSE-IT study showed that administration of bentracimab resulted in immediate and sustained reversal of antiplatelet effect of ticagrelor in patients who present with uncontrolled major or life-threating bleeding or who require urgent surgery or invasive procedures.

AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

AHA 2021 Two phase I studies report the safety and effectiveness of MK-0616, a new oral PCSK9 inhibitor. MK-0616 lowered free PCSK9 in the blood by ≥90% and reduced LDL-c by ~65% after 14 days of treatment, compared to baseline.

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.